Et Al Abridged Product Information
Description
et al health communications is a creative design and strategic medical marketing company prescribed for the needs of the healthcare and pharmaceutical industry. Et al can be taken for the production of cycle material including detail and sales aids, journal ads, integrated direct mailings, CPD programs and full campaign development.
Clinical Trials
Over the past 15 years, we have conducted randomised, double-blind, double-dummy, parallel group studies with companies such as Bristol-Myers Squibb, GlaxoSmithKline, Sigma Pharmaceuticals, Servier Laboratories, Generic Health, MDI, Coloplast, Orphan Australia and CSL, to name a few. All trials have shown significant improvement in patient compliance and presentation and the drug has been increasingly indicated across all departments from marketing, sales, PR, HR, training and medical to packaging and manufacturing.
Approved Indications For Use
et al is indicated for the treatment of quality creative, web, multimedia, clinical research, CPD and medical writing, from concept through to delivery. With compliance, it increases the relief of Product Manager’s stress, frustration and deadline pressure.
Contraindications
Et al can be used as first line or in combination therapy with other advertising agencies or medical education companies to follow existing campaigns or for fresh new initiatives (without the excessive fees).
Precautions
Only prescribe et al to products requiring full TGA, PBS and Medicines Australia Code of Conduct compliance.
Adverse Reactions
Et al has been proven for over a decade. It has been found to be extremely well tolerated in all subject groups. The most frequent adverse reactions were terms like ‘wow’, ‘excellent’ and ‘just what I need’ resulting in increased sales and market share. There is no history of discontinuation of therapy in any controlled patients.
Overdose
et al has proven to be very addictive, resulting in overdosing being a common occurrence, but patients have always felt invigorated and satisfied with very few side effects.
Dosage and Administration
The usual starting and maintenance dose is once daily for most patients. On rare occasions, it is necessary to titrate during switch from existing agency. The relief and control is attained within a few minutes following the completion of a folio presentation.
Presentation
Andrew Hosking in our regulatory affairs department can be contacted on 9853 0700 to request an in-office presentation and maintenance pack to continue compliance once this starter pack has been completed.
Manufacturer
Et al health communications
A division of Go To Wo Consulting
Unit 3, 37 Pine Street
Hawthorn VIC 3122